The Ubiquitous Target Question for Anticancer Modalities
Continuing on this theme that Joel has raised in his recent post (“CD19 and BCMA – ‘What if This is as Good as it Gets?’”), I would like to add a few additional points. One, Joel notes the limited universe of validated targets. The issue of target discovery remains critical for Oncology. And while many companies are leveraging diverse platforms to surface completely new targets (such as Immatics and Atreca), other biotechs are exploiting unique twists and keen understanding of the biology of cancer cells to identify novel targets, as defined by novel epitopes for antibodies and related, that are unique to cancer cells, but which are occurring on known, validated targets, meaning know cell surface proteins (like GO Therapeutics, targeting novel cancer-specific glycosylation).
Feb 6, 2020
How to Approach SEO in Healthcare and Pharma
Search Engine Optimization (SEO) seems to be an endlessly murky topic for all involved. Nowhere is this truer than in the twin worlds of healthcare and pharmaceuticals. Let’s try to clear up SEO here today and get to its core. 
View Jan 14, 2020